Latest Intelligence on Pharmaceuticals and Healthcare in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Virco: looking into the future of AIDS therapy

Published By Datamonitor
17 Jul 2001
ResearchWire
ResearchWire

Vinka alkaloids: market to fall 17% by 2007

Published By Datamonitor
16 May 2001
CommentWire
CommentWire

Vertex: Positive results for cystic fibrosis drug

Vertex has completed a Phase II trial of a small-molecule oral drug, VX-770, which targets the basic defect that occurs in cystic fibrosis (CF). The trial has only been performed in 20 patients from a small, genetically distinct subset of the CF population. However, the results are encouraging and indicate an alternative approach to traditional reactive management of CF.

Published By Datamonitor
28 Mar 2008
CommentWire
CommentWire

Vertex Pharmaceuticals: strong evidence for VX-770 as a potential novel treatment method

Vertex Pharmaceuticals' novel cystic fibrosis treatment VX-770 has demonstrated strong efficacy in a Phase III trial, meeting the primary endpoint and key secondary endpoints. VX-770 targets the underlying cause of the disease, and, if approved, would offer a novel treatment approach.

Published By Datamonitor
25 Feb 2011
CommentWire
CommentWire

Verta/SciClone: new drug could limit TB spread

According to preliminary results, Russian pharma company Verta's new immune system enhancing drug may have a significant impact on TB contagion. Although the treatment regime is arduous, involving five daily injections, there could be a significant market for SCV-07 in locations where Directly Observed Treatment can be implemented.

Published By Datamonitor
01 Oct 2002
CommentWire
CommentWire

Vernalis: revised R&D focus after Frova decision hits home

Vernalis's decision to undergo major restructuring is a direct result of the non-approval of the company's sNDA submission for Frova, for the treatment of menstrual migraine. A successful application had been anticipated to double the revenue potential of Frova.

Published By Datamonitor
22 Feb 2008
CommentWire
CommentWire

Vernalis: Frovelan concerns a headache for shareholders

Published By Datamonitor
20 Sep 2001
CommentWire
CommentWire

Vernalis: benefiting from SB's regulatory headaches

Published By Datamonitor
14 Dec 2000
CommentWire
CommentWire

Vernalis/Endo: gain in menstrual migraine

New phase III data have confirmed previous results showing Vernalis and Endo's Frova to be an effective preventative treatment for menstrual migraine. This should pave the way for the migraine drug's approval in this additional indication. Anticipated in 2007, this approval is then expected to transform Frova's sales significantly.

Published By Datamonitor
08 May 2006
Expert View
Expert View

Vectibix's possible label expansion may only lead to a modest increase in uptake

Amgen has received a positive opinion from the CHMP for Vectibix in combination with chemotherapy in the first- and second-line treatment of mCRC. This is a significant step forward for Vectibix, but if it is approved, market competition will result in only a modest increase in uptake and commercial reward.

Published By Datamonitor
27 Jun 2011

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.